How to Reduce Antimicrobial Resistance (AMR)

1. Antimicrobial Stewardship Programs (ASPs)

• Prospective audit and feedback: An infectious disease physician or pharmacist regularly reviews broad-spectrum antibiotic prescriptions (e.g., carbapenems, ceftazidime-avibactam) and recommends de-escalation where appropriate. This has consistently reduced unnecessary broad-spectrum use and cut C. difficile rates.
• Formulary restriction: Limiting the antimicrobials available in a hospital formulary prevents indiscriminate use and reduces unnecessary drug expenditure.
• Preauthorization: Clinicians must obtain approval before using certain agents, acting as a front-line filter against inappropriate prescribing.

2. Optimizing Prescribing Practice

• Only prescribe when clearly indicated: Antibiotics should be withheld for viral infections (colds, flu, most sore throats).
• Identify the infection source first: Clinical examination to confirm bacterial vs. viral etiology before prescribing.
• Collect samples before starting treatment: Blood cultures, wound swabs, urine cultures - all before the first antibiotic dose. Delaying cultures until after therapy denies the lab the chance to grow the causative organism.
• Use the narrowest effective spectrum: Broad-spectrum agents should be reserved for polymicrobial infections or when culture results are unavailable and the patient is critically ill.
• De-escalate promptly: Once culture and sensitivity results are back, step down to the narrowest effective agent (targeted therapy).
• Optimize duration: Many conditions (e.g., uncomplicated community-acquired pneumonia, urinary tract infections) require far shorter courses than historically prescribed. "Complete the course" dogma is now being revised - stopping when clinically resolved is increasingly evidence-based for selected conditions.
• IV-to-oral switch: Transition to oral therapy as soon as the patient can tolerate it - reduces hospital stays and IV line-related complications. - Scott-Brown's Otorhinolaryngology, p. 168

3. Infection Prevention and Control (IPC)

• Hand hygiene: The single most effective measure to prevent healthcare-associated infections (HAIs). Alcohol-based hand rubs and handwashing with soap must be universal.
• Standard and transmission-based precautions: Contact precautions (gloves, gowns) for patients with MRSA, VRE, carbapenem-resistant organisms; droplet/airborne for respiratory pathogens.
• Environmental decontamination: Regular cleaning of clinical surfaces, patient equipment, and isolation rooms.
• Catheter and device care bundles: Central-line bundles, urinary catheter bundles, and ventilator bundles substantially reduce device-associated infections that often require broad-spectrum treatment.
• Vaccination: Prevents the infections that drive antibiotic demand. Pneumococcal, influenza, H. influenzae type b, meningococcal, and COVID-19 vaccines all reduce the burden of disease that would otherwise be treated (and sometimes mistreated) with antibiotics. - Red Book 2021

4. Surveillance

• Local antibiograms: Each hospital should produce regular antibiograms summarizing local resistance patterns, guiding empiric prescribing choices.
• National systems: The WHO's Global Antimicrobial Resistance and Use Surveillance System (GLASS), launched in 2015, standardizes AMR surveillance worldwide, enabling cross-border trend detection.
• Real-time electronic monitoring: Linking prescribing data, culture results, and clinical outcomes in electronic health records enables faster detection of outbreaks and misuse patterns.
• Outbreak investigation: Rapid molecular typing (e.g., whole-genome sequencing) of resistant pathogens allows healthcare teams to identify and break chains of transmission. - Park's Textbook of Preventive and Social Medicine

5. Rapid Diagnostics

• Point-of-care rapid tests: C-reactive protein, procalcitonin, and rapid antigen tests help distinguish bacterial from viral illness, supporting antibiotic withholding.
• Rapid molecular diagnostics (PCR panels): Identify pathogens and resistance genes within hours.
• MALDI-TOF mass spectrometry: Rapid organism identification from blood cultures in minutes instead of days.
• AI-assisted stewardship: A 2025 systematic review (PMID 39955846) found AI-driven approaches integrated with electronic records significantly improved antibiotic prescribing quality in stewardship programs.

6. Regulation of Antibiotic Access

• Prescription-only status: In many low- and middle-income countries, antibiotics are available over the counter, enabling self-treatment with wrong agents, wrong doses, and wrong durations - accelerating resistance. Enforcing prescription requirements is a foundational control.
• Banning substandard/counterfeit drugs: Low-quality preparations with sub-therapeutic concentrations of active ingredients are a major driver of resistance in developing countries.
• Restricting agricultural use: Antibiotics used as growth promoters in livestock directly contribute to resistance in human pathogens. The CDC and FDA both link animal antibiotic use to human resistance. The WHO recommends reducing all non-therapeutic antibiotic use in food-producing animals. - Park's Textbook, p. 7617

7. Research and Development

• New antibiotic classes: No new class of antibiotic with a novel mechanism of action has reached the market since the 1980s. The pipeline remains thin. Public-private partnerships such as the Global Antibiotic Research and Development Partnership (GARDP) and government incentives (market exclusivity, push/pull funding) are needed to make antibiotic development economically viable.
• Bacteriophage therapy: Viruses that selectively kill bacteria, being explored for multidrug-resistant infections.
• Anti-biofilm agents and efflux pump inhibitors: Non-antibiotic approaches that enhance existing drug efficacy against resistant organisms.
• Vaccines against resistant pathogens: Vaccines against MRSA and Klebsiella pneumoniae are in development.

8. The "One Health" Framework

Key Recent Evidence

• ESCMID stewardship guidelines for emergency departments (PMID 39029872) - a 2024 systematic review/practice guideline specifically addressing stewardship in high-pressure prescribing environments.
• Health economics of ASPs (PMID 41756763) - 2024 scoping review confirming ASPs are cost-effective at both hospital and system levels.
• AI-driven ASP optimization (PMID 39955846) - 2025 systematic review supporting AI tools as adjuncts to human-led stewardship.